Krystal Biotech 2023 Q4 Financial Results and Business Update

Krystal Biotech reported strong 2023 results following FDA approval of VYJUVEK, its first corrective therapy for dystrophic epidermolysis bullosa (DEB), with $50.7M in net product revenue in just two quarters. The company achieved significant pipeline expansion with 5 active clinical trials planned for 2024 and maintained a robust balance sheet of $594.1M in cash and investments.